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Therapy by human immunoglobulin G (IgG) concentrates is a success story ongoing for
decades with an ever increasing demand for this plasma product. The success of IgG con-
centrates on a clinical level is documented by the slowly increasing number of registered
indication and the more rapid increase of the off-label uses, a topic dealt with in another
contribution to this special issue of Frontiers in Immunology. A part of the success is the
adverse event (AE) profile of IgG concentrates which is, even at life-long need for ther-
apy, excellent. Transmission of pathogens in the last decade could be entirely controlled
through the antecedent introduction by authorities of a regulatory network and installing
quality standards by the plasma fractionation industry. The cornerstone of the regulatory
network is current good manufacturing practice. Non-infectious AEs occur rarely and mainly
are mild to moderate. However, in recent times, the increase in frequency of hemolytic
and thrombotic AEs raised worrying questions on the possible background for these AEs.
Below, we review elements of non-infectious AEs, and particularly focus on hemolysis and
thrombosis.We discuss how the introduction of plasma fractionation by ion-exchange chro-
matography and polishing by immunoaffinity chromatographic steps might alter repertoire
of specificities and influence AE profiles and efficacy of IgG concentrates.
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INTRODUCTION – THE TINGE OF THE DARK SIDE OF
THERAPIES WITH IMMUNOGLOBULIN CONCENTRATES
Since the initial clinical use of immunoglobulin G (IgG) con-
centrates of human origin, transmission of pathogens and non-
infectious adverse events (AEs) were reported (1–7). Before the
mid 90s, transmission of pathogens depended on the pool size
and the fractionation methods used, particularly the polish-
ing steps of an IgG concentrate (8). Mode of fractionation,
Abbreviations: ACA, anti-complementary activity= unwanted spontaneous
complement-activating capacity of an Ig concentrate; AE, adverse event; BCR, B
cell receptor; BT, body temperature; C3a/C3a[desArg], anaphylatoxin C3a and its
arginine deprived form which were detected together; CH50, total complement
hemolytic activity 50%; cGMP, current good manufacturing practice; CVID, com-
mon variable immunodeficiency; DAT, direct antiglobulin test; DVT, deep venous
thrombosis; HA, hemolytic anemia; Hb, hemoglobin; HR, heart rate; IC, immune
complex; IgA, immunoglobulin A; IgA1, subclass 1 of IgA; IgA2, subclass 2 of IgA;
IgAD, IgA deficiency; IgG, immunoglobulin G; IgM, immunoglobulin M; IL-1ra,
interleukin 1 receptor antagonist; IL-6, interleukin 6; IL-8, interleukin 8; IMIG,
immunoglobulin G concentrate for intramuscular application; IR, infusion rate;
IVIG, immunoglobulin G concentrate for intravenous application; IEP, isoelec-
tric point; ITP, immune thrombocytopenic purpura; LDH, lactate dehydrogenase;
MERS, middle east respiratory syndrome; MW, molecular weight; NAb, natural
antibody or autoantibody; PKA, prekallikrein activator; PE, pulmonary embolism;
RBC, red blood cell, erythrocyte; SARS, severe acute respiratory syndrome; SCIG,
immunoglobulin concentrate for subcutaneous application; sIgAD, selective IgAD;
TCR, T cell receptor; TNFα, tumor necrosis factor alpha; V-region, variable region
of antibodies, TCR and BCR; vCJD, variant Creutzfeldt-Jakob disease.
i.e., cold-ethanol or ion-exchange chromatography, contaminants,
route of application, i.e., intra muscular (IMIG), intravenous
(IVIG), or subcutaneous (SCIG), the rate of increase of the exoge-
nous IgG in the circulation of the recipient over time and, last
but not least an eventually existing risk factor from patients’
side (Figure 1) as well as incorrect handling of the concentrate
are factors having a role in inducing non-infectious AEs related
to administration of IgG concentrates (Table 1). IgG concen-
trates represent a defined part of the adaptive immune system,
are isolated from pooled human plasma of at least 1000 donors,
which contribute to the repertoire diversity in the final prod-
uct. Therapies with IgG concentrates manufactured according
to regulators requirements are acknowledged to be safe in gen-
eral. This does not exclude the occurrence of AEs which in
their majority are rare and clinically mild to moderate. Below,
we like to give a few insights into various aspects and possible
mechanisms of AEs.
PATHOGEN SAFETY OF IgG CONCENTRATES – HOW TO
EXCLUDE THE MENACES FROM A DARK AND FRIGHTENING
ENVIRONMENT
Manufacturing of modern IgG concentrates has to occur in a
regulatory framework and the quality standards implemented by
the plasma fractionating industry (Figure 2). The cornerstone of
the regulatory framework is current good manufacturing prac-
tice (cGMP). A pillar of pathogen safety is the validation of
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FIGURE 1 | Provoking the dark. AEs to therapeutic IgG concentrates
might be evoked by several factors. These are listed in the introductory part
andTable 1. Contemplating on the active ingredient of the concentrates,
the administration of the IgG molecules inevitably results in the interactions
of the exogenous IgG with the various parts of the immune system of the
recipient and vice versa.This interaction in its principle generates an
inflammatory condition. A key parameter deciding on the intensity of such a
condition is the rate of increase over time of exogenous IgG in the
circulation of the recipient. Insert to figure (shadowed): ∆IgG in the
circulation over ∆time is dependent on the combination of infusion rate (IR)
and the strength of the solution applied. Main figure: the mode of
application, i.e., intravenous or subcutaneous, are additional factors being
decisive for kinetics and the area under the curve of generation of
pro-inflammatory mediators and for passing the individual threshold
(short-dashed line) for a clinically noticeable AE. The threshold in turn
depends on eventually exiting risk factors form the patient side. Although
the area under the curve might be the same for low (long-dashed line) and
high (solid line) IRs, at high IR, the system might not be able to cope with
the extent of reactions. At low IR (long-dashed line), all the events might
remain below the threshold of clinically observable AE. Subcutaneously
applied IgG concentrate reaches the circulation slowly and systemic AEs
are less frequent than with IVIG. In contrast, local mild to moderate AEs are
more frequent with SCIG.
virus inactivation and virus elimination methods by validating an
already performed step of the fractionation process or by introduc-
tion of dedicated steps (Figure 3). A hallmark of virus elimination
introduced in the late 90s in Berne by the team of Christoph Kempf
is the large-scale virus filtration technique (formerly also termed
“nanofiltration”) (8). Meanwhile, virus filtration became a versa-
tile tool to eliminate a variety of pathogens, the suspected agent of
variant Creutzfeldt-Jakob disease included. Thanks to the tightly
implemented regulatory framework, pathogen safety of plasma
products is at a level never reached before. This is well supported by
the fact of reports missing in the last decade of transmission by IgG
concentrates of emerging viruses (SARS coronavirus, West Nile
Virus, MERS coronavirus, and others), zoonotic pathogens, or the
agent of variant Creutzfeldt-Jakob disease (vCJD). Furthermore,
the development of specific mass screening techniques might help
to eradicate in any blood product the transmission of vCJD in the
future (9).
HOW THE SHADOWMIGHT GROW – SOME BASIC INSIGHTS
INTO POSSIBLE MECHANISMS OF NON-INFECTIOUS
ADVERSE EVENTS
The human immune system is in charge of controlling invading
organisms and mediates homeostasis. The immunoglobulin pools
in mammals (IgM, IgG, and IgA) to its smaller part provide defense
and to the larger part homeostasis. Human IgG has a role in both.
Efficient host defense is supported by “immune antibodies.” These
have undergone somatic hypermutations and have in their vast
majority narrow specificities and high affinities. Antibodies, gener-
ated in absence of external stimuli are termed “natural antibodies”
(NAbs). They occasionally recognize self structures. In general, the
V(D)J genes of NAbs are in germ-line configuration or have under-
gone a few somatic hypermutations only. Furthermore, they have
broad specificity, are of low affinity (with exceptions) and high
avidity (10). These NAbs can participate in primary host defense,
i.e., at a time point when an immunologic reaction has not pro-
vided the specific antibodies, react, e.g., with repetitive structures
which can be found on bacteria or viruses (11). The self-reactive
NAbs, which we like to term physiologic autoantibodies, comprises
various populations of antibodies such as (i) those able to inter-
act through their complementary variable regions (V-regions)
with the V-regions of circulating and membrane-bound (BCR)
immunoglobulins and the T cell receptor (TCR) β-chain variable
region, providing a peripheral immune network (V-connected
network) (10); (ii) the NAbs reacting in a non-idiotypic manner
with the hinge region of immunoglobulins (12, 13); (iii) popula-
tions of NAbs showing a wide variety of specificities toward growth
factors, cytokines, or anaphylatoxin (10); (iii) and the population
reacting with the soluble or membrane-bound forms of cell surface
molecules having immunological importance, the last described
being the Fc receptors CD16 and CD32 (14). Antibodies reacting
with docking structures for viruses or bacteria can have addi-
tional first-line defense potential (15). These populations of NAbs
were described having a peripheral immune network homeostatic
and anti-inflammatory function (16, 17). Although the primor-
dial humoral proteins comprising the complement and lectin-like
proteins in the plasma play a definite role, another population of
self-reactive NAbs reacting with, e.g., epitopes conserved over the
evolution apparently has tissue homeostatic function and might
support the efficient removal of roughly 1012 altered/senescent
cells of the body per day (for references see below). The sig-
nal for research on NAbs in IVIG was the description of IgG
autoantibody-mediated immune thrombocytopenia (ITP) being
corrected by infusion of a polyclonal, polyspecific IgG concentrate
(18, 19). This research has expanded ever since.
The populations of immune antibodies and NAbs in IgG
concentrates upon infusion/injection inevitably react with occa-
sional pathogens, toxins, or superantigens and concomitantly
infusion/injection also results in recognition of a wide array of
tissue antigens and V-regions of the recipient’s immune sys-
tem. Reactions with tissue antigens and V-regions are con-
veyed by the self-reactive antibodies of the many donors in
the IgG concentrate. Vice versa, the recipient’s immune sys-
tem reacts with the infused IgG. A bewildering wide range
of possible reactions can occur which primarily are depen-
dent on the immune status of the recipient at the time of
therapy and to a smaller part on the IgG concentrate(s).
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Table 1 |The tinge of the dark.
Symptoms
and signs
Frequency IRR
or total
dose
PRR System Class, severity,
and duration
Part of the product
likely being
involved in AEs
Fatigue Common (SCIG as
well)
No Constitutional or
systemic (generalized)
Immediate, mild,
transient
Malaise Common No Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Fever Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Flushing Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Chills Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Anorexia Common No Constitutional or
systemic (generalized)
Immediate, mild,
transient
Myalgia Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Arthralgia Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Joint swelling Common Yes Yes Constitutional or
systemic (generalized)
Mild, transient
“Flu-like” symptoms Common Yes Yes Constitutional or
systemic (generalized)
Immediate, mild,
transient
Increase in A (dimers)
Anaphylactoid
symptoms
Rare
Complement
activation
Immune complexes
(presence of acute
infection)
No Yes Constitutional or
systemic (generalized)
IgA: acute to
immediate; other late,
severe transient
I: IgA, very rare immune
complexes
Full blown
anaphylaxis
Rare
Complement
activation (in the
presence of acute
infection)
No Yes Constitutional or
systemic (generalized)
Late, severe, hopefully
transient (ICU)
I: IgA, very rare immune
complexes
Headache Common Yes Yes Neurologic Immediate, mild,
transient
Increase in A
Migraine Common Yes Yes Neurologic Transient Increase in A
Dizziness Common Yes Yes Neurologic Transient Increase in A
Aseptic meningitis Rare No No Neurologic Delayed, moderate,
transient
Increase in A
Diffuse pain, muscle
pain
Rare Yes Yes Neurologic Transient Increase in A
Dysesthesia Rare Contributes Neurologic Increase in A
Weakness Rare Contributes Neurologic Increase in A
(Continued)
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Table 1 | Continued
Symptoms
and signs
Frequency IRR
or total
dose
PRR System Class, severity,
and duration
Part of the product
likely being
involved in AEs
Persistent headache Rare Yes Neurologic Delayed, moderate Increase in A
Shortness of breath Common Dose Yes Respiratory
Bronchospasm Common Yes Yes Respiratory
Pleural effusion Rare Dose Contributes Respiratory Severe, transient
TRALI Rare Dose Likely Respiratory Late, severe, transient
(ICU)
Hypotension Common Yes Yes Cardiovascular Immediate, mild,
transient
Hypertension Common Yes Contributes Cardiovascular Immediate, mild,
transient
Tachycardia Common Yes Yes Cardiovascular Immediate, mild,
transient
Chest/back pain Common Yes Yes Cardiovascular Immediate, mild,
transient
Arrhythmia Rare Dose Contributes Cardiovascular Severe, hopefully
transient
Myocardial infarction Rare Dose Contributes Cardiovascular Severe to fatal Increase in A
Anorexia Common Gastrointestinal
Nausea Common Yes Yes Gastrointestinal Immediate, mild,
transient
Vomiting Common Yes Yes Gastrointestinal Immediate, mild,
transient
Cramping Common Yes Contributes Gastrointestinal
Diarrhea Common Contributes Gastrointestinal
Colitis Rare Contributes Gastrointestinal Late, severe
Tubular swelling Rare Dose Contributes Renal Severe, reversible;
scars might remain
E: sucrose>> other
sugars
Renal failure Rare Contributes Renal Delayed. severe, ICU Increase in A
(Complement deposition)
Infusion site pain,
swelling, erythema
Common (SCIG
more frequent)
Cutaneous Immediate, mild,
transient
SCIG: volume
Urticaria Common Yes Cutaneous Increase in A
Non-specific macular
or maculopapular
eruptions/eczema
Common Yes Cutaneous Increase in A
Pruritus Common Contributes Cutaneous
Erythema
multiforme
Rare Contributes Cutaneous Increase in A
(Continued)
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Table 1 | Continued
Symptoms
and signs
Frequency IRR
or total
dose
PRR System Class, severity,
and duration
Part of the product
likely being
involved in AEs
Cutaneous vasculitis Rare Dose Contributes Cutaneous Delayed, severe
Hemolysis (clinically
not significant)
Common Yes Contributes Hematologic Delayed, moderate,
transient
Acute
hemolysis/hemolytic
anemia
Rare Yes Yes Hematologic Delayed, severe Increase in A
Thrombotic
phenomena (DVT,
stroke, cardial
infarction)
Rare Yes Yes Hematologic Severe, ICU Increase in A
Hyperviscosity Rare Yes Contributes Hematologic Immediate Increase in A
Neutropenia Rare Yes Hematologic Delayed, mild, transient Increase in A
Blood borne
infectious disease
Rare No No Microbiological Late, severe I: blood borne viruses,
spongiform
encephalopathy agent
Inappropriate
handling before
infusion
No Immediate, mild to
severe
A: incomplete dissolution
of lyophilized product;
denaturation and
aggregate formation due
to foam
E: lyophilized product
dissolved to result in too
high concentrations;
lyophilized product
dissolved to result in too
high osmolality; low
temperature of
concentrate at the time of
infusion
The various manifestations of AEs in recipients of polyvalent immunoglobulins. Frequency, severity, duration, timing, possible causes, risk factors.
A, active ingredient= IgG; I, impurities; E, excipients/stabilizers; “immediate”, immediate reaction – within 6 h from the onset of infusion; “delayed”, delayed reac-
tion – 6 h to 1week after infusion; “late”, late reaction: weeks to months after infusion; IRR, infusion rate-related; PRR, patient-related risk factors (acute infection at
the time of infusion); ICU, intensive care unit; SCIG, IgG concentrate for subcutaneous application.
The therapeutic effect achieved depends on the disease treated,
and can depend on the concentration reached locally, i.e., can
have agonistic or antagonistic effects (17, 20–22). In summary, it
is our opinion that IgG concentrates always provide more or less
the same “bouquet” of IgG specificities (similarity); however, it is
the recipient’s actual immune condition which decides from which
IgG specificities the patient’s derailed immune system is profiting
(diversity).
Parameters of IgG-mediated AEs are: (i) the content in the
product of biologically highly active likely beneficial ingredients
that have to be kept under control (e.g., content of “dimers”
devoid of remarkable complement activation in vivo; see below),
and the content in unwanted active ingredients that have to be
discarded during manufacturing (alloantibodies); (ii) impurities
such as IgA (anaphylactoid reaction); (iii) activated coagulation
and contact activation factors (thromboembolic events) and; (iv)
excipients such as sucrose (osmotic nephrosis). Below, we like
to add and contemplate on how fully native IgG molecules not
harmed by the manufacturing process might add to AEs. The
above mentioned inevitable interaction of the exogenous IgG
with the immune system of the recipient and vice versa in its
principle might evoke an inflammatory condition. The sum of
the potentially beneficial reactions might overshoot and lead to
AEs (Figure 1). The principle of induction of mild inflammatory
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FIGURE 2 | Staying within a regulatory network is mandatory for
remaining at the sunny side of the moon. Handling of blood/plasma
products to obtain therapeutic goods has to be performed within a
regulatory framework. Manufacturing of stable blood product has to adhere
strictly to current good manufacturing practice (cGMP). Application of
cGMP starts from the moment of collecting whole blood and isolation of
plasma thereof (R= recovered plasma) or the machine-supported collection
of plasma (S= source plasma, apheresis plasma). Application of cGMP
ends at delivery of blood/plasma products to health care professionals. Not
following cGMP can lead to withdrawal of a plasma product from the
market from one to the other day.
conditions upon each infusion of a well-tolerated IVIG was con-
firmed when several dozen normogammaglobulinemic volunteers
in all cases except one, showed a more or less moderate inflam-
matory reaction as indicated by the increase of tumor necrosis
factor alpha (TNFα) at 2.5 h post initiation of infusion. The only
person in the cohort not showing a measurable TNFα increase
was a woman caring at home for her brother with full blown
AIDS (22).
Subcutaneously applied IgG concentrate reaches the circulation
slowly and systemic AEs are less frequent compared to IVIG but
they are not absent (23–28) (a case of unintentional i.v. application
of SCIG is not considered). In contrast, local mild to moderate AEs
are more frequent with SCIG (29). In summary, the intensity of
the resulting AEs is depending on the immune status of the recip-
ient, the infusion rate (IR), e.g., how rapidly the active ingredients
(the various IgG specificities), the impurities, and the excipients
reach the circulation of the recipient. Thus, the i.v. application has
the highest chance for the occurrence of AEs.
In the early days of IVIG therapy, complement-mediated “ana-
phylactoid” (i.e., immediate) and “phlogistic” (i.e., inflamma-
tory) AEs were distinguished (30, 31). The complement-mediated
AEs were considered to be caused by aggregates in the product
(“spontaneous complement activation” or anti-complementary
activity or ACA) or by in vivo formation of immune complexes
(ICs, patient’s condition related; e.g., subclinical infections or the
unnoticed presence of anti-IgA antibodies) and therefore only IgG
concentrates with low or absent ACA is accepted by authorities for
human use. Below, we present one instructive case of each type of
reaction.
IMMEDIATE ADVERSE EVENTS – THE RAPID ONSET OF DARKNESS
The first reports of rapid onset AEs concerned either the applica-
tion of complement-activating fractions in an IgG concentrate or
the in vivo formation of complement-activating ICs (2–4). A very
rare but potentially fatal condition is the formation of IgA/anti-
IgA complexes in patients being initiated on replacement therapy
and having serum IgG antibodies against infused IgA not rec-
ognized before the start of the IVIG infusion (32). Prerequisite
for the presence of anti-IgA antibodies is the most common pri-
mary immunoglobulin defect, i.e., selective IgA deficiency (sIgAD)
or IgAD associated with diminution of other immunoglobulin
classes. IgAD is defined by serum levels of <0.05 or <0.07 g/L
(depending on laboratories). A marked diminution of serum
IgA consistent with IgAD in various ethnic groups is estimated
being 1:155 to 1:18,550 (33). The mean frequency in Caucasians
is approximately 1:700 (34). Up to 40% of patients with IgAD
have been reported having anti-IgA antibodies in the serum with
titers ranging between 1:4 and 1:262,144. In approximately 10% of
patients with common variable immunodeficiency (CVID), and
occasionally in patients with other primary immunodeficiency
diseases, measurable anti-IgA can be detected (35, 36). These anti-
bodies are predominantly of the IgG class, but anti-IgA antibodies
of other immunoglobulin classes have been described as well (37,
38). The reason for their emergence remains unknown.
Taken the above numbers, the infusion of human-derived prod-
ucts containing IgA resulting in severe anaphylactoid type AEs
should be considerable. This is not the case (39). Questions about
the clinical relevance of above numbers emerge as soon as blood
banks (i) estimate the theoretical risk of IgA anaphylactic reactions
(32); (ii) assess the relation of severe IgAD with the presence or
absence of anti-IgA antibodies (40); (iii) screen donors for very
low IgA levels in order to become able to provide blood and
plasma-derived products free of IgA and find a considerably lower
frequency than expected (41). Alternatively, the test systems may
not reliably detect anti-IgA antibodies being as yet insensitive and
inaccurate or – at least – do not correspond to the clinically rel-
evant fraction of antibodies. This comes to mind when a more
close look to “anti-IgA” gives “unexpected” results, including “anti-
IgA” in blood donors with normal serum IgA level or “anti-IgA”
that cannot be neutralized with purified IgA (42); or when blood
products containing proven anti-IgA do not elicit severe AEs (43).
Among patients on replacement therapy, those with CVID
may rarely develop severe immediate AEs (32). The discrepancy
between anti-IgA positive patients and frequency of AEs raises the
question about the nature of the many reported anti-IgA antibod-
ies and also raises the question about the immunologic condition
which allows the formation of anaphylactoid anti-IgA antibodies.
There might be some logic in supposing that anaphylactoid anti-
IgA cannot evolve at IgA levels otherwise fulfilling the definition
of IgAD. Such a condition would constantly generate ICs which in
turn could activate complement, react with immune cells, and be
deposited in lung and kidney. Indeed, Horn et al. found anti-IgA
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FIGURE 3 | Active measures in fractionation to stay on the sunny side
of the moon. (*) depicts possible sites for validating the efficiency of
already established fractionation steps or for introducing dedicated
pathogen reduction and/or inactivation measures. Histo-blood group
antibodies were made responsible for hemolytic AEs. Reduction of these
during the manufacturing process is possible by introduction of an
immunoaffinity chromatographic step in order to reduce anti-A and anti-B
titers.
antibodies in CVID patients missing IgA+ B cells and presenting
with IgA levels <0.0009 g/L, a level which is more than 50- to 70-
fold lower than the threshold for IgAD (44). However, a possibility
for an IgA-mediated anaphylactoid reaction at measurable IgA
serum levels might exist. Serum IgA contains approximately 85%
subclass 1 of IgA (IgA1) and only 15% subclass 2 of IgA (IgA2).
Selective deficiency of IgA2 and – although evidence is lacking –
the presence of a highly specific anti-IgA2 antibody theoretically
could elicit a severe AE.
The kinetics of anti-IgA after infusion of blood products have
been studied in a few cases. In these patients, a fall in anti-IgA
titers has been noticed followed by an increase during subsequent
weeks or months. This suggests that at appropriate proportions,
IgA of the infused material and anti-IgA present in the patients’
serum combine with each other to form ICs. In turn, ICs activate
complement that are bound and eliminated by macrophages most
likely leading to cytokine release. The increase in anti-IgA titers
over time indicates that the infused IgA-containing product has
a booster effect (36, 37, 45). Such boosting effect together with
the presence of anti-IgA before the application of an IgG con-
centrate can be taken as the ultimate confirmation of a supposed
IgA/anti-IgA reaction. Figure 4 depicts a well-documented case of
IgA/anti-IgA reaction in a patient who progressed from sIgAD to
CVID. The events during the first 12 h at occasion of the first infu-
sion of IVIG were as follows (shadowed area in Figure 4): 2 min
after the start of the infusion, having received eight drops of an
IgG solution (IgA < 1.2 g/L; 3% solution), she experienced a flush,
back pain, rigors, difficulty in breathing, and hypotension. The
infusion was immediately stopped. After approximately 1 h, the
reaction has weaned, and 2 h later the patient felt well again, and
the infusion of total 6 g IgG could be continued without further
complications. Although the patient fairly assured having never
received any blood or plasma product in the past, the follow-up of
her anti-IgA titers from before infusion to 1 year later confirmed a
true anaphylactoid reaction mediated by anti-IgA, as the anti-IgA
became undetectable immediately after the infusion and showed
a boosting phenomenon during the following months. True ana-
phylactoid reaction was further confirmed by follow-up of total
complement hemolytic activity (CH50) on the day of infusion.
Interestingly enough, the CH50 value reached its nadir at the end
of the infusion when the patient had no complains. Although a
single case only, the events during the first infusion call for the fol-
lowing remarks: (i) severe AEs most likely occur at concomitant
complement and cell activation with cytokine release; (ii) infu-
sion of minute to low amounts of IVIG hours before the main
infusion can “anergize” cells and stop release of pro-inflammatory
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FIGURE 4 | An individual’s slithering into the dark. A female patient has
been suffering from recurrent airway infections since adolescence,
occasionally complicated by pneumonia. At age 34, selective IgA deficiency
was diagnosed. Ten years later, she was hospitalized with pneumonia.
Within these 10 years, her serum IgG had dropped from 7 to 0.87 g/L
(long-dashed line) and IgA was undetectable. The diagnosis was corrected
into CVID, and IVIG replacement therapy was initiated (shadowed area). Two
minutes after the start of the infusion of a 3% IgG solution (IgA < 1.2 g/L;
3% solution), she experienced a flush, back pain, rigors, difficulty in
breathing, and hypotension. The infusion was immediately stopped and
later continued without further complications (see text). The confirmation of
a true anaphylactoid reaction due to anti-IgA in the serum of the patient was
achieved by follow-up of anti-IgA (solid line) and CH50 (short-dashed line).
cytokines; (iii) “anergized” cells loose reactivity toward ongoing
formation of ICs and complement activation products.
A non-complement-mediated anaphylactoid reaction was
ascribed to the unforeseen release of elastase and other pro-
inflammatory substances from neutrophils activated by the forma-
tion of in vivo IgA/anti-IgA complexes. Complement activation or
mast cell-dependent release of vasoactive substances was excluded
as pathogenic mechanisms. Although the IgA/anti-IgA complexes
usually do not cause clinically relevant neutrophil degranulation
within the circulation, the presence of a rare genotype encod-
ing a novel gain-of-function IgG receptor on neutrophils may
provoke premature degranulation by these complexes. This phe-
nomenon was only relevant in hypogammaglobulinemic patients
in the presence of in vivo IgA/anti-IgA complexes (46). The low
prevalence of this genotype combined with an IgAD or CVID
may add how to explain the rarity of serious anaphylactoid reac-
tions in newly IVIG-treated patients. Authors share the opinion of
Janne Björkander who at occasion of a discussion panel “Dilem-
mas in Diagnosis and Management of Antibody Deficiencies: Ask
the Experts” held at occasion of the 58th Annual Meeting of the
American Academy of Allergy, Asthma & Immunology (AAAAI),
New York City, March 1–6, 2002 came to the following conclusion:
a clinician has to be aware of the risk, particularly at occasion of
first infusions, but otherwise IgA is not a major concern (from
tape record).
PRO-INFLAMMATORY CYTOKINES – THE PHLOGISTON OF THE DARK
In the early days of Ig-therapy, the nature of the “phlogistic” AEs
was obscure. However, it was already known that an AE can be
prevented or its evolution halted when the patient receives a low
dose of IVIG first or the infusion is stopped early and is continued
several hours later. Hours later the infusion can be (re)started at
high rates without further problems (Figure 5). One of the authors
had a particular opportunity to get an insight into what a“phlogis-
tic reaction” might be. At the occasion of a voluntary infusion of
an investigational liquid IVIG, he encountered a severe flu-like AE
of more than 12 h duration. Before injection, the investigational
liquid preparation had passed all release criteria for human use,
including spontaneous complement activation assessed by ACA
and was free of prekallikrein activator (PKA). In those days, assays
for cytokines in biological samples just began to become available
and were included into the parameters assessed in the study. Infu-
sion was stopped after 1 h because of a drop of pulse rate and heavy
discomfort provoking the laconic comment by the proband’s tech-
nician who was taking samples:“you look green.”The infusion was
continued after another 90 min when the heart rate had almost
normalized. The infusion could be completed within an addi-
tional 3.25 h (a total of 0.4 g/kg b.w.) without further aggravation
of malaise. The leukocyte count transiently had dropped to a nadir
of 40% at 2 h followed by a leukocytosis peak at 8 h. Complement
activation, as assessed by generation of C3a/C3a[desArg] and the
formation of the terminal complement complex C5b-9, apparently
did not occur: the C3a/C3a[desArg] value reached a maximum
of 260 ng/mL (norm: <200 ng/mL) at 7 h while the C5b-9 value
never moved outside the normal range. Instead, a sequence of
rapid transient massive increases of pro-inflammatory cytokines
was observed: (i) TNFα started to increase 30 min post initiation of
infusion from a value of 20 pg/mL to a peak value at 2 h which was
above the calibration range of the test kit of 1500 pg/mL; (ii) inter-
leukin 8 (IL-8) increase started after 1 h from 29 pg/mL and peaked
at 2.5 h with 4400 pg/mL post initiation of infusion; (iii) inter-
leukin 6 (IL-6) secretion started after 1 h with an undetectable level
and peaked at 4 h with 345 pg/mL. All pro-inflammatory cytokines
fell sharply while the second part of the infusion was still ongoing.
The day after infusion, the pro-inflammatory cytokine profiles
were back to normal and the flu-like syndrome was gone. In
contrast, interleukin 1 receptor antagonist (IL-1ra) values started
increasing at 1.5 h (300 pg/mL), peaked at 4 h (>32,000 pg/mL),
and decreased slowly to reach a value of 10,500 pg/mL 24 h after
initiation of the infusion. Soluble TNF receptor p75 level started
at 2.25 ng/mL, reached a peak with 16.5 ng/mL at the same time as
IL-1ra, and 24 h after initiation of infusion was still at 10.5 ng/mL.
Thus, in this normogammaglobulinemic subject similar cytokine
profiles and leukocyte number changes were observed as reported
for hypogammagobulinemia under replacement therapy (47, 48).
A series of further experiments with investigational and mar-
keted IVIGs was performed. All IgG concentrates were analyzed for
their molecular weight (MW) distribution. The most remarkable
differences emerged in the MW range of dimers while the presence
of minute amounts of higher oligomers could not be excluded with
certainty. Below, we will use the term “dimers” for that fraction of
IgG with higher MW. Subsequent findings indicated that levels
of “dimers”>12% were responsible for complement-independent
cell activation and cytokine release. The TNFα peaks assessed at
2.5 h post initiation of infusions correlated with “dimer” content
of the IVIGs and mirrored a clinical score of AEs (49–51).
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FIGURE 5 | Clinical signs of the “phlogiston” of the dark. A CVID patient
received his first infusion of IVIG (a 3% solution). Despite the start of the
infusion at an infusion rate [IR, (C)] of only 10 drops per minute and
incremental increase by five drops every 30 min, rise of heart rate [HR, (A)],
and of body temperature [BT, (B)] after 2 h of the initiation of infusion
indicated the onset of a “phlogistic” reaction and infusion was stopped.
Stop of the infusion for 30 min immediately let drop HR and BT. Restarting
the infusion showed some negative effect and infusion was stopped after
application of 9 g IgG [dashed line, (C)]. The next day the rapid infusion of
additional 9 g of IgG was without consequence on BT and HR, indicating
silencing of cells releasing mediators of inflammation.
A few years before a complement-independent induction of
a hypotensive factor by IgG di- and oligomers was reported in
animal experiments (52). A key role for macrophages in the gen-
eration of the hypotensive lipid factor was identified as platelet-
activating factor, being induced by dimers and polymers (53, 54).
Several years later, the dimer-mediated AEs in animal experiments
were confirmed (55, 56). Yet, at the same time, the dimer con-
tent of IVIG apparently correlated with the clinical efficacy in a
murine ITP model (55, 57). Variables such as “IR,” “genetic back-
ground,” “endogenous immunoglobulin levels,” or “proportional
fraction of polymers versus dimers” may impact on the balance
between the phlogiston (being cytokines, active lipid substances,
or a combination of factors) and the therapeutic efficacy (blocking
IgG receptors on liver/spleen macrophages to prevent clearance of
“opsonized” material such as platelets in ITP). As of today, reports
on release of cytokines in humans in association with AEs or
tolerability toward dimers remain scarce and to the best of our
knowledge studies in humans of causative factors/fraction in an
IgG concentrate has not been adequately addressed (47, 48, 58–61).
In IgG preparations, various forms of dimers might be present:
formed through covalent binding (62) by denaturation, hydropho-
bic interactions of the Fc-parts, and by idiotype/anti-idiotype
interactions, as part of the V-connected network of peripheral
immune homeostasis (63). For a commercially viable fractiona-
tion process, pooling of donated plasma is mandatory in order
to obtain a volume of starting material large enough to cover
ever increasing costs for documentation, in-process, and batch-
release testing as it is required by cGMP. Pooling also intends
smoothing the batch-to-batch differences in antibody titers, a goal
apparently difficult to achieve to levels as theory might imply
(64). Consequences of pooling are on the one hand the enrich-
ment of public/common immune antibodies while diluting out
individual specificities; on the other hand, the antibodies of the
immune network of an individual donor are exposed to those
of many other donors. The more individuals contribute to the
pool, the more complex the possible “immune-network” inter-
actions among IgA, IgG, and IgM will become. The subsequent
fractionation process has far-reaching effects on immunoglobu-
lins from a given pool: only trace amounts of IgA and IgM are
retained in the final product, i.e., IgG is deprived of its counter-
parts of the V-connected immune network. The IgG molecules
of the homeostatic network “naked” at their V-regions can inter-
act with each other at random combining site-interactions of
single donor-derived monomeric IgG (65), otherwise not exist-
ing in vivo. This interaction is largely reversible. With increasing
numbers of donors included into the pool, the immune network
recognition among the “naked” IgG molecules of the V-connected
network becomes more and more complex, and the dimer and
lower oligomer content in the resulting IgG concentrate increases
(66–68). In lyophilized IgG concentrates, the dimer formation is
“frozen” at a low level while in liquid preparations an equilibrium
between monomers and dimers is achieved over time reaching
a dimer content of 12% or more if not hampered by stabilizers.
Specificities, as far as they have been addressed, in the dimer frac-
tion considerably differ from the monomeric fraction (69–73). In
conclusion, the immunomodulatory efficacy of IgG concentrates
in part depends on the capacity and extent to form “dimer” frac-
tions devoid of remarkable complement activation in vivo. The
“art” of manufacturing a liquid IgG concentrate is not to eliminate
the monomeric IgG having potential for “dimer” formation but to
inhibit extensive“dimerization.”In summary,AEs might be associ-
ated with the induction of pro-inflammatory cytokines in absence
of measurable complement activation in vivo where all regulatory
mechanisms and removal processes of a body are at disposition.
At reasonable IRs in the open system of the human body, clin-
ically relevant systemic complement activation apparently needs
oligomers formed of three or more IgG molecules.
THE MISSING OXYGEN ON THE DARK
SIDE – IMMUNOGLOBULIN-INDUCED HEMOLYSIS
There are multiple reports of Ig-induced hemolytic anemia (HA)
in patients receiving high doses of IVIG (60, 74–110) (Table 2;
Figure 6; www.adrreports.eu). By spontaneous reporting, risk
factors recognized for Ig-induced hemolysis include beside high
doses (more than 100 g IVIG over 2–4 days), female gender and
histo-blood group type A, B, or AB of recipients.
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Table 2 |The missing oxygen on the dark side – Ig-induced hemolysis in recipients of polyvalent immunoglobulins.
Publication Number
of patients
Blood group Monthly Ig
dosage (mg/kg)
DAT Eluted antibody Alloantibody
passively
administered
Hemoglobin drop (g/L) Outcome
Quinti et al. (110) 8 A+ (5), A- (1),
O+ (2)
Low IgG (2), IgG and
C3d (4)
anti-A (5), anti-C
(1), anti-C and
anti-D (1)
anti-A, anti-C,
anti-D
6.4, 1.5, 5.1, 1.4, 6.9,
1.1, 1, 1
Recovery (7),
death (1)
Desbourouh et al. (76) 1 AB+ High IgG and C3 anti-A and anti-B anti-A and anti-B
and anti-D
6.5 Recovery
Mohamed et al. (77) 1 A+ High IgG anti-A nd 4 Recovery
Rink et al. (78) 3 A+ (2) High IgG nd nd 1.2, 3.8, 4.4 Recovery
Berard et al. (79) 4 A+ (2), B+ (1),
AB+ (1)
High IgG anti-A (1), anti-B
(1), anti-A and
anti- B (1)
nd 2.9, 5.8, 5.8, 3.7 Recovery
Michelis et al. (60) 1 A+ High IgG anti-A nd 3.5 Recovery
Pintova et al. (80) 2 AB+, A+ Low IgG anti-A nd 6.6, 7.2 Recovery
Morgan et al. (81) 3 AB+(1), A- (1),
A- (1)
High IgG anti-A (2), anti-A
and anti-B (1)
anti-A (2), anti-A
and anti-B (1)
4.8, 5.0, 1.8 Recovery
Welles et al. (82) 1 nd High IgG nd nd 4.3 Death
Canadian Group (83) 20 A (14), AB (6) High IgG nd nd 3.2, 2.8, 5.1, 5, 5.6, 5,
3.5, 4.1, 7, 3.2, 5.6,
3.2, 6.6, 2.9, 3.1, 4,
3.9, 7.8, 4.9, 4.8
Recovery (10),
death (1),
unknown (8)
Gordon et al. (84) 4 A+ (3), AB+ (1) High IgG nd nd 5.3, 5.5, 4.8, 4.8 Recovery
Kahwaji et al. (85) 16 A+ (10), A- (2),
B+ (3), AB+ (1)
High IgG nd anti-A, anti-B 5.3, 4.7, 5.6, 4.9, 5.8,
5.7, 3.3, 2.4, 3.1, 4.0,
3.6, 2.1, 2.2, 2.8, 5.3,
1.9, 2.6, 3.0
Recovery
Daw et al. (86) 16 A+ (7), AB+ (1),
AB- (1), B+ (6),
O- (1)
High IgG anti-A (6), anti-B
(4)
anti-A, anti-B 1.4, 3.6, 4.3, 3.6, 3.2,
3.4, 3, 4.7, 5.1, 5, 2.4,
8, 5.2, 1.3, 3
nd
Yin et al. (87) 1 AB+ High Negative nd anti-A and anti-B
and anti-D
nd Recovery
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Table 2 | Continued
Publication Number
of patients
Blood group Monthly Ig
dosage (mg/kg)
DAT Eluted antibody Alloantibody
passively
administered
Hemoglobin drop (g/L) Outcome
Coghil et al. (88) 1 A+ High IgG anti-A anti-A 4 Recovery
Chamouni et al. (90) 1 AB+ High IgG nd nd 8 Recovery
Karaaslan et al. (91) 1 nd High IgG nd nd 3.9 Recovery
Trifa et al. (92) 1 AB+ High IgG anti-A and anti-B anti-A and anti-B 7.8 Recovery
Nagakawa et al. (94) 1 A+ High IgG nd nd 2 Recovery
Wilson et al. (95) 12 A+ (11), O+ (1) High (10), low (2) IgG anti-A (9), anti-A
and anti-D (2),
anti D (1)
nd 3.7, 3.8, 1, 1.6, 1.9, 2.9,
1.4, 1.9, 3, 1.8, 1, 0.9
nd
Tamada et al. (97) 2 nd High IgG anti-A, anti-B nd nd nd
Thomas et al. (99) 1 A+ High IgG anti-A anti-A 6.3 Recovery
Comenzo et al. (100) 1 nd High nd nd nd nd Recovery
Okubo et al. (102) 1 A+ High IgG anti-A anti-A nd nd
Hillyer et al. (103) 1 AB+ High IgG anti-A, anti-B nd nd Recovery
Nicholls et al. (104) 2 nd High IgG anti-A, anti-A
and anti-D
nd nd nd
Kim et al. (105) 2 B+ High IgG anti-B nd nd nd
Brox et al. (106) 1 nd High IgG anti-A nd nd nd
Clinical and immunological characteristics of patients described in case reports. Numbers in parenthesis indicate the number of patients with the given condition.
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FIGURE 6 |The missing oxygen on the dark side: Ig-induced hemolysis in patients on Ig treatment. Black bars indicate the number of patients with a
given clinical condition.
A significant proportion of patients receiving IVIG develop a
positive direct antiglobulin test (DAT) detectable after 24 h for up
to 10 days after the IVIG infusion (109, 110). However, it should be
underlined that the DAT positivity due to the factors mentioned
above (111, 112) is not sufficient per se to diagnose hemolysis
and DAT positivity does not necessarily imply the presence of
active hemolysis. DAT-positive mild hemolytic reactions can be
easily missed and the true incidence of such reactions is difficult
to document without careful clinical and laboratory follow-up.
In the majority of reports on HA, intravascular red blood cell
(RBC) destruction via complement activation or extravascular
RBC sequestration and removal by the reticulo-endothelial system
was proposed to result from IgG alloantibodies with specificity for
RBC antigens A, B, D, or C.
Hemolytic anemia induced by high-dose IVIG has an aver-
age incidence of 5.8% (85). Low-dose IgG replacement therapy
is considered universally as safe, and only few cases of hemoly-
sis following low-dose IVIG or SCIG administration have been
described (80, 95, 110). A baseline WBC and RBC count prior to
IVIG initiation and a close clinical and laboratory follow-up was
suggested as a useful tool for early diagnosis and treatment. A pos-
sible work up might be to check hemoglobin (Hb) level prior and
48–78 h after Ig infusion. In case of a drop of Hb, the presence
of DAT, an increase in unconjugated bilirubin, lactate dehydro-
genase (LDH), and reduced haptoglobin level, followed by a rise
in reticulocyte count should be assessed (Figure 7). We system-
atically reviewed case reports related to IVIG-induced hemolysis
from 1987 to 2014 and identified 29 articles containing reports of
109 patients. Baseline characteristics of the patients are shown in
Table 2. When available, blood group, DAT, Hb drop, and outcome
are indicated. All reports showed positive DAT, except for a case of
Yin et al. (87); in this case, DAT was performed 10 days after IVIG
administration and the DAT negativity might have been due to a
rapid removal of sensitized RBCs.
In the majority of patients, the outcome was positive: 106 out of
109 patients recovered with or without packed RBC transfusions;
three patients died after HA, with the hemolytic episode represent-
ing a precipitating factor of a severe underlying condition. Elution
experiments were performed and the search for blood group anti-
bodies revealed anti-A and anti-B specificity in the majority of
cases; anti-D specificity was assessed in four reports, often asso-
ciated with other specificities (95, 106, 110). A search for other
specificities such as anti-band 3 or anti-Gal was not performed.
Only one report detected anti-C specificity in three patients; in
one of them associated with anti-D irregular antibodies (110).
Although studies were restricted to blood group antibodies, this
finding demonstrated that polyvalent IgG preparations might con-
tain clinically significant non-blood group antibodies, which are
not part of the lot-release criteria in that their titration is not
yet required by the European Pharmacopeia. Antibodies in HA,
such as anti-C, may have unexpected hemolytic consequences
(113–117). Beside passive transfer of alloantibodies, IgG adminis-
tration also has been demonstrated to lead to unspecific enhanced
erythrocyte sequestration, in particular, in patients with under-
lying inflammatory disorders (109, 118). In 2009, the Canadian
IVIG Hemolysis Pharmacovigilance Group elaborated criteria to
define an “IVIG-induced hemolysis” (83). They included a reduc-
tion of Hb levels≥1 g within 10 days after Ig administration, with
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FIGURE 7 | Monitoring for evidence of oxygen missing at the dark side.
Diagnostic algorithm for Ig-induced hemolysis according to criteria
elaborated by the Canadian Group (83).
appearance of a positive DAT and, at least, two of the following
criteria: increase in the reticulocyte count, elevation of LDH and
unconjugated bilirubin serum levels, low haptoglobin, hemoglo-
binuria, hemoglobinemia, presence of significant spherocytosis,
in the absence of alternative causes of anemia. The passive trans-
fer of IgG alloantibodies through IgG concentrates is difficult
to explain as polyvalent IgG is prepared from plasma of thou-
sands of donors. Since immunization to RBC alloantigens can
occur because of past transfusions or pregnancy, the hypothetical
numbers of alloimmunized plasma donors should be rather low.
Recently, other mechanisms underlying alloimmunization related
to molecular mimicry have been demonstrated (119). The mecha-
nism of high-dose IVIG-induced HA is complex and it might vary
from patient to patient. IVIG cause hemolysis due to: (i) disease-
associated pre-coating of RBCs; (ii) IgG with hemolysis triggered
by passive transfer of IgG binding to blood group antigens; (iii)
transfer of high levels of alloantibodies to RBC pre-coated at a
low level only; or (iv) transfer of clinically tolerable levels of isoag-
glutinins plus transfer of additional RBC-reacting physiological
autoantibodies. Indeed, hemolytic reactions could not be related
exclusively to transfer of alloantibodies. Hence, antibodies other
than histo-blood group alloantibodies (pre-)coated to RBCs might
contribute to hemolysis in IgG recipients need to be identified. In
addition, hemolytic episodes may possibly be precipitated by some
sort of complexed/denatured IgG that co-purify with other IgG in
the product (76, 109, 118, 120). Recently, a two hit mechanism for
IVIG-induced hemolysis has been proposed: the passive transfer
of alloantibodies through IVIG representing the first hit and the
underlying inflammatory state representing the second hit (121).
Nowadays all commercial Ig products have to undergo anti-A and
anti-B testing and regulatory requirement ask for respective IgG
antibody titers of ≤1:64 at 5% solution strength (w/v) (103, 104).
Nevertheless, hemolysis might occur even in recipients of IgG
products that meet these specifications (76). Consequently, it has
been suggested that IgG recipients should be monitored for clinical
signs and symptoms of hemolysis (122).
REDUCTION OF HISTO-BLOOD GROUP A AND B ALLOANTIBODIES IN
IgG CONCENTRATES RAISES THE CHANCE FOR STAYING ON THE
SUNNY SIDE OF THE MOON
With the detection of the immunomodulatory potential of IgG
concentrates, their clinical use has continuously increased (123).
To cover the need, at a first glance, an increase of the volume of
plasma fractionated seems to be the most convenient option. How-
ever, this might economically not be viable because fractionation
of plasma products is interconnected (124) and before increasing
output of one product (e.g., IVIG), the market absorbance of the
other products as well (e.g., albumin) must be ascertained. On
a longer-run, a more viable option is to improve recovery. Con-
sidering recovery, the cold-ethanol fractionation apparently has
reached its limits. As of today, four manufactures have invested
into a“modern”fractioning technique on the basis of ion-exchange
chromatography. Ion-exchange chromatography allows elevated
recovery at high purity. As of today, five IVIGs, one SCIG, and one
anti-D concentrate are fractionated by ion-exchange chromatog-
raphy. Pharmacovigilance has shown that all chromatographically
fractionated IVIG and SCIG, more or less prominently, show a
tendency for elevated frequencies of hemolytic AEs. Anti-A and
anti-B alloantibody titers are now lot-release criteria (see above)
as they constitute the major risk parameter for hemolytic reactions
mediated by IgG concentrates. To overcome the threat of end up
on the dark side of the moon, two manufacturers have taken mea-
sures to reduce anti-A and anti-B titers in their IgG products. One
measure chosen was adsorption of the alloantibodies by affinity
chromatography (125). Reported reduction in both alloantibodies
was significant and levels were similar to those in cold-ethanol frac-
tionated immunoglobulins (126). The other measure chosen was
reduction in anti-A using an automated indirect agglutination test
for donor screening and exclusion of high-titer donations (approx-
imately 5.1%) from plasma pooling and fractionation (127). This
measure reduced anti-A in the IgG concentrate by one titer step.
To ensure staying on the safe and sunny side, the manufacturer
has announced the introduction of an alloanti-A and alloanti-
B immune-affinity chromatography step into the manufacturing
process (128). Preliminary results indicate depletion in anti-A and
anti-B by >80% in investigational lots. Subsequently, we want to
discuss possible consequences of (extensive) removal of antibodies
reacting with histo-blood group antigens A and B.
REASONING ABOUT ANTIBODIES REACTING WITH TERMINAL SUGARS
OF THE MAJOR HISTO-BLOOD GROUP ANTIGENS A AND B
Three facts have initiated our thinking about possible conse-
quences of removal of histo-blood group A and B reacting
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antibodies from IgG concentrates. (I) In collaboration with Hans
U. Lutz, formerly Biochemistry ETH Zurich, we have observed the
non-intended removal of natural anti-C3 autoantibodies regulat-
ing complement activation by large-scale immune-affinity adsorp-
tion of IgA from an IgG concentrate (129). Anti-C3 antibodies
belong to the family of “NAbs” and have a particular role in home-
ostasis: they control activation of complement, among others, in
the frame of NAb-mediated opsono-phagocytosis of altered or
senescent cells, including RBCs (130–132). Thus, the intention to
target one particular antibody by affinity chromatography might
reduce that antibody specificity but at the same time affect other
specificities as well. (II) It should be kept in mind that the blood
groups A and B are in fact “histo-blood group” antigens, i.e., they
are also found on white blood cells, T lymphocytes, and proteins
and also can be found in soluble form (133). Alloantibodies react-
ing with histo-blood group antigens A and B thus have much
broader tissue recognition than RBCs only. In addition, alloanti-
A and alloanti-B belong to the population of NAbs recognizing
non-self and most likely participate in primary host defense (134).
(III) In contrast to cold-ethanol fractionation, where low titers of
alloanti-A and alloanti-B are achieved on basis of their isoelec-
tric points (IEPs), the (extensive) immune-affinity removal might
affect a much wider IEP range, thereby removing broadly react-
ing antibodies and impairing some desirable functions of the IgG
concentrate. Thus, the struggle for staying on the sunny side of the
moon might have consequences for the antibody repertoire in an
IgG concentrate.
Antibodies reacting with terminal di-, tri-, and tetra-
saccharides belong to the large family of human anti-glycan NAbs.
Histo-blood group A and B epitopes in terminal position are tetra-
saccharides. Alloantibodies to these tetra-saccharides are found in
the plasma of healthy individuals depending on the blood group
they have. A considerable body of research into the nature of these
NAbs has been performed so far, all using for isolation the cor-
responding terminal di- or tri-saccharides (135–137). Recently,
the repertoire and epitope specificity of such immunoglobulins
was addressed in depth by including the tetra-saccharide as well
(138, 139). It proved that serum of healthy individuals contain
respectable amounts of di- or tri-saccharide-reacting NAbs. These
NAbs proved to be pseudo-anti-A and pseudo-anti-B NAbs as they
are not reacting with the tetra-saccharide of histo-blood groups
A and B. In contrast, alloanti-A and -B antibodies able to react
with tetra-saccharides are reacting with the corresponding termi-
nal di- and tri-saccharides. Reasoning about the biological role
of these “high-titer and population conservative” anti-di- and
anti-tri-saccharide NAbs and the consequence of their potential
removal by immunoaffinity is outlined below.
A population of the anti-glycan NAbs are the anti-αGal NAbs
which recognize Galα1-3Gal and Galα1-3(Fucα1-2)Gal epitopes.
Anti-αGal NAbs have been described being xenoreactive, recog-
nizing bacterial Galα1-3Gal (140) and having tissue homeosta-
tic function. The daily removal of altered/senescent cells of the
body is ~1012. Removal is mainly mediated by apoptosis (no
inflammation, no necrosis). RBCs, when they do not encounter a
pathological condition, over their life span of 100–120 days remain
intact although they shrink, do not undergo apoptosis but progres-
sively become senescent, mainly due to cumulative oxidative stress.
Removal of intact RBCs with a daily turnover of ~2× 1011, corre-
sponding to ~20 g cell mass, is effectuated by increased exposure
of otherwise cryptic structures such as spectrin, band 3, or αGal
epitopes. These exposed structures are recognized by low affin-
ity, high avidity, C3-bearing NAbs, which promote the efficient
removal of intact senescent RBCs (130, 141, 142). Immunoaffinity
adsorption by tri-saccharides columns of di- and tri-saccharide
reacting NAbs from IgG concentrates can eliminate anti-histo-
blood A and B alloantibodies while it also eliminates αGal and this
might have a Janus effect. The face directed to the sun tells that
adsorbing αGal NAbs reacting with altered and senescent self on
RBC might prevent an increase in the IgG load of RBCs over the
threshold level of relevant hemolysis in individuals at risk. The face
directed to the dark indicate that adsorption of tissue homeostatic
antibodies might deprive an IgG concentrate of potentially bene-
ficial antibodies. Although they are NAbs, tri-saccharide reacting
antibodies can be induced by feeding bacteria bearing the corre-
sponding carbohydrate epitopes (134). These inducible NAbs are
considered to participate in primary host defense. Other antibod-
ies possibly involved in primary host defense are the anti-αGal
NAbs. They show a broad specificity and can react with a num-
ber of related αGal-terminated oligosaccharides, including those
on bacteria (143). Thus, the immunoadsorption of di-and tri-
saccharide reacting NAbs might diminish the potential of an IgG
concentrate to mediate primary host defense. Therefore, when
choosing affinity resins for immunoadsorption, there might be
some aspects worth to consider.
In summary, the principles of avoiding co-fractionation
through cold-ethanol fractionation (144) versus immune-affinity
removal of histo-blood group alloantibodies can have an impact
on the presence of homeostatic and first-line defense antibodies.
According to present knowledge, only resins coated with the cor-
responding tetra-saccharides can ascertain the selective removal
of histo-blood group alloantibodies presumably involved in HA.
Resins coated with the corresponding di- and tri-saccharides also
remove blood group alloantibodies, however not selectively. Such
resins in addition might remove a broad range of NAbs present
in IgG concentrates at relative high amounts. In the literature,
the use of tri-saccharide-coated resin was reported (145–147). We
have found no information available in the public domain indi-
cating which type of resin is/will be used for reduction of the
histo-blood group alloantibodies in large-scale fractionation of
IgG. Furthermore, we suggest that the effect of reduction of anti-A
and ant-B reacting antibodies by immune-affinity on the antibody
repertoire of IgG concentrates can only be assessed by, e.g., using
pathogens/commensals, which share the saccharide epitopes, that
have been used to coat the affinity resins or alternatively by expos-
ing senescent RBCs stripped off the IgGs coated in vivo. Finally,
techniques are required, which allow detection of low affinity, high
avidity NAbs.
THROMBOSIS – FALLING INTO A DARK LUNAR CRATER
IVIG administration-related AEs, including thrombosis, have been
extensively described (148). Thrombotic AEs are severe AEs and
patients with risk factors require a special care. Reported aver-
age incidence of IVIG-induced thrombosis ranges from 3 to
13% (149). Recognized risk factors for IVIG-induced thrombosis
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FIGURE 8 | Falling into a dark lunar crater while being on Ig treatment. Bars indicate the number of patients with a given clinical condition and Ig-mediated
thrombosis.
include male gender; age>60; diabetes; renal insufficiency, dyslipi-
demia; hypertension; immobility; coronary disease; pre-existing
vascular disease, family history of early thromboembolic dis-
ease; atrial fibrillation, high-dose and high-speed IVIG infu-
sions. IVIG-induced thrombosis is reported both as venous events
such as thrombosis stroke, pulmonary embolism (PE), deep
venous thrombosis (DVT), and arterial ischemia events such as
myocardial infarct and stroke. The mechanisms leading to IVIG-
associated thrombosis are still not completely clear; three main
mechanisms have been proposed, emphasizing the role of an
increased blood viscosity causing a hypercoagulable state (150),
the role of anticardiolipin antibodies passively transferred through
IVIG (151), and the role of factor XIa or other biologically highly
active factors passively transferred via IgG concentrates, such as
PKA. Avoiding activated coagulation factors in IgG concentrates
starts with appropriate anticoagulation of donated blood/plasma,
i.e., careful mixing of anticoagulant and sample over the whole
donation process. Alterations in an established manufacturing
process neglecting appropriate controls can also lead to increased
risk of transmission of activated coagulation factors. High MW
proteins passively transferred by IVIG are probably contributing
to this phenomenon (152). In patients with other risk factors,
such as vascular disease, the increase in blood viscosity can pre-
cipitate thromboembolic events. As elderly individuals are prone
for such AEs, we like to point to the possibility of elevated
altered/senescent self-reacting with infused homeostatic NAbs
being a possible factor facilitating thrombotic events as well. A rela-
tionship between IVIG administration and cerebral vasospasm
has also been suggested by Sztajzel et al. (153); blood viscosity
is a determinant for oxygen delivery to the tissues, and changes
in viscosity can lead to a reduction in cerebral or myocardial
perfusion.
We systematically reviewed case reports related to IVIG-
induced thrombosis from 1986 to 2014 (Figure 8). Literature
search identified 35 articles containing reports concerning 65
patients (6, 24, 149, 154–183). When data were available, diagno-
sis, risk factors, the number of IVIG infusion prior to thrombosis
event, and outcome have been indicated. Baseline characteristics
of the patients are shown in Table 3. High-dose IVIG induced
thromboembolic events in 59 patients at low to medium IVIG
doses. Marie et al. (163) observed that the frequency and type of
arterial events was inversely related to the time elapsed from IVIG
infusion; almost 50% (23 versus 21 reports) of arterial ischemic
events occurred within 12 h following IVIG, while about 75% of
venous thrombosis occurred after more than 24 h. No correlation
between number of infusions and occurrence of AE was observed.
The main risk factors observed in this review were hypertension
(19 cases, 33% of prevalence), previous vascular disease (18%),
and dyslipidemia (17%). Average mortality for thrombotic events
was 10% (arterial ischemia 9% versus venous thrombosis 11%,
PE representing the main venous fatal event). Predicting IVIG-
induced thrombosis is difficult. Risk factors should be assessed for
each patient including instrumental exams when needed. Doppler
ultrasound can be useful as early diagnostic tool for thrombosis
or to detect the presence of abnormal blood flow especially after
prolonged immobility. IVIG should be administered at low IR
to reduce the risk. The administration of antiplatelet or antico-
agulant prophylaxis was suggested in patients with several risk
factors (162). However, thrombotic events have been reported
even after several previous uncomplicated courses of treatment.
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Table 3 | Falling into a deep lunar crater – Ig-induced thrombosis in recipients of polyvalent immunoglobulins.
Publication Number of
patients
Age Diagnosis Ig dosage Predisposing
factors
Number of IVIG
infusion prior to
thrombosis event
Thrombosis
(arterial or
venous)
Time from
the last
infusion
Outcome
Vinod et al. (154) 1 >65 Guillain-Barrè High First Arterial 72 h Recovery
Sin et al. (157) 1 <65 Solid organ
transplantation
High First Arterial 48 h Recovery
post-emergency
renal transplant
Min et al. (24) 1 <65 CVID Low (SCIG) Hypercoagulability
(oral contraceptive)
Several Venous nd
Rajabally et al. (149) 5 <65 (2),
>65 (3)
CIDP High Diabetes (2),
hypertension (2),
immobility (4),
coronary disease (2),
arrhythmia (1)
First (3),
several (2)
Arterial (3),
venous (2)
14 days Recovery (4),
death (1)
Al-Riyami et al.
(156)
1 11 ITP High Several Venous 10 days Recovery
Iroh et al. (155) 1 13 ITP High Estrogen treatment First Venous 12 h Death
Barada et al. (158) 1 11 XLA Low Several Venous nd nd
Lee et al. (159) 1 56 ITP High First Venous 72 h Recovery
White et al. (160) 1 43 Dermatomyositis High First Arterial 2 h Recovery
Feuillet et al. (161) 1 38 Multiple sclerosis High Oral contraceptives Seventh Venous 6 days Recovery
Marie et al. (162) 2 51, 55 Polyarteritis nodosa
(1), polymyositis (1)
High Third, 15th Venous (2) 2 h, 7 days Recovery
Marie et al. (163) 6 76, 49, 63,
45, 64, 64
AHA (1),
polymyositis (5)
High Hypertension (3),
hypercholes-
terolemia (3)
Second, sixth,
several (4)
Venous (3),
arterial (3)
2 days, 6 h (5) Recovery
Geller et al. (165) 1 28 Streptococcal toxic
shock syndrome
High First Venous 8 days Recovery
Sheehan et al.
(167)
1 43 Pemphigus vulgaris High Immobility,
hypertension
First Venous 16 days Recovery
Hefer et al. (164) 1 85 ITP High Hypertension,
chronic
myelogenous
leukemia
Second Arterial 3 h Recovery
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Table 3 | Continued
Publication Number of
patients
Age Diagnosis Ig dosage Predisposing
factors
Number of IVIG
infusion prior to
thrombosis event
Thrombosis
(arterial or
venous)
Time from
the last
infusion
Outcome
Feuillet et al. (166) 1 38 Multiple sclerosis High Oral contraceptives First Venous nd Recovery
Vucic et al. (168) 7 57, 69, 75,
81, 79, 62,
80
CIPD (4), anti-MAG
neuropathy (1),
multifocal motor
neuropathy (1)
High Hypertension (3),
hypercholes-
terolemia (3),
previous stroke (2),
arrhythmia (1)
Second (1), third
(2), several (5)
Arterial (6),
venous (1)
1 h (2), 2 days (3),
2 weeks (2)
Recovery (5)
Stamboulis et al.
(169)
1 36 CIPD High Heavy smoker First Arterial nd Recovery
Katz et al. (170) 2 67, 65 Pemphigus
vulgaris,
dermatomyositis
High Hypertension Second, first Arterial (1),
venous (1)
6 h Recovery
Zaidan et al. (171) 3 47, 65, 70 GBS (1),
CIDP (2)
High Hypercholesterolaemia
(1), diabetes (2)
Third (1),
several (2)
Arterial (3) 1 h (2), 1 day (1) Recovery (2)
Brown et al. (172) 3 70, 91, 42 CVID Low Diabetes (1),
myocardial
infarction (2)
Arterial (3) 6 h Recovery
Evangelou et al.
(173)
1 54 CVID Low High platelets count Several Venous 24 h nd
Emerson et al. (174) 2 54, 33 ITP, Evans
Syndrome
High Obesity (1) Second Arterial (2);
venous (1)
2 h, 2 days Death (1),
recovery (1)
Alliot et al. (175) 1 63 ITP High Hypertension Fifth Venous 3 days Death
Sherer et al. (176) 2 High Venous
Elkayam et al. (177) 4 60, 41, 67,
67
ITP, polymyositis,
connective
disease, CIPD
High Hypercholesterolemia
(2), hypertension (2)
several (3),
first (1)
Arterial 4 days Recovery
Go et al. (178) 1 52 ITP High First Venous 1 day Recovery
Turner et al. (179) 1 60 Miller-Fisher
syndrome
High Fifth Arterial 5 days Recovery
Harkness et al.
(180)
1 40 CIDP High Hypercholesterolemia Arterial and
venous
7 days Recovery
(Continued)
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In such cases, patients should be examined for signs and symptoms
of thrombosis during each courses of IVIG.
Immunoglobulin G concentrates are widely acknowledged to
offer a safe, high-dose, long-term therapy option for a variety of
diseases. AEs occur rarely and mainly are mild to moderate. Devi-
ations from this rule of thumb are addressed by authorities and
the plasma fractionation industry to achieve corrections. Above,
we have reviewed two types of AE which have shown elevated
frequency in the near past. We tried to give some insights which
might help in reducing frequencies of AEs bed side.
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